Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer

뉴스 본문을 불러오고 있어요.

Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer | 웨이프 WAPE

Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer

기사 요약

관련 종목

댓글 —